Nhat Giang Minh
Nhat Giang Minh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hai Hoang Nguyen
Department of Intensive Cardiovascular Care and Cardiovascular Imaging, Nhan dan Gia Dinh Hospital , Ho Chi Minh City
3 shared publications Duc Tan Vo
Department of Diagnostic Imaging, University Medical Center of Ho Chi Minh City , Ho Chi Minh City
2 shared publicationsHai H. Nguyen
2 shared publications- Hoa Ngoc Chau
Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam
2 shared publications Chau Ngoc-Hoa
Vietnam National Heart Association , Ho Chi Minh City
1 shared publicationDaichi Maeda
Department of Cardiology, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (40)
Pulmonary Embolism, Silent Stroke, and an Occult Caval Thrombus
- 7 October 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (40)
Open AccessPulmonary Embolism, Silent Stroke, and an Occult Caval Thrombus
- Open Access
- 1 May 2026
- Published by The Korea Association of Clinical Ultrasound in Clinical Ultrasound
- Vol. 11 (1) , 19-30
Left Atrial Function Assessment by Echocardiography: From Fundamentals to Techniques
Echocardiographic evaluation of the left atrium (LA) has developed into a fundamental component of cardiovascular assessment for both healthy individuals and patients with heart disease. Traditionally considered a passive conduit, the dynamic interplay between the left ventricle (LV) and LA during the cardiac cycle is now recognized to actively influence LV filling pressures. Although measurement of LA size remains important, it is insufficient to fully reveal the chamber's unique physiological role. Recent advances have underscored the clinical significance of LA functional assessment, which encompasses three distinct phases—reservoir, conduit, and booster pump—that are readily accessible via echocardiography. Notably, an LA functional analysis has predictive value beyond LV diastolic dysfunction and has been incorporated in the latest American Society of Echocardiography guidelines and European Association of Cardiovascular Imaging consensus recommendations as a key criterion for grading LV filling pressure. For primary physicians, understanding the progression of LA functional assessment techniques, along with their respective strengths and limitations, is essential for selecting the modality most appropriate for a patient’s cardiovascular profile.
- 1 May 2026
- Published by The Korea Association of Clinical Ultrasound in Clinical Ultrasound
- Vol. 11 (1) , 19-30
Open AccessLeft Atrial Function Assessment by Echocardiography: From Fundamentals to Techniques
Echocardiographic evaluation of the left atrium (LA) has developed into a fundamental component of cardiovascular assessment for both healthy individuals and patients with heart disease. Traditionally considered a passive conduit, the dynamic interplay between the left ventricle (LV) and LA during the cardiac cycle is now recognized to actively influence LV filling pressures. Although measurement of LA size remains important, it is insufficient to fully reveal the chamber's unique physiological role. Recent advances have underscored the clinical significance of LA functional assessment, which encompasses three distinct phases—reservoir, conduit, and booster pump—that are readily accessible via echocardiography. Notably, an LA functional analysis has predictive value beyond LV diastolic dysfunction and has been incorporated in the latest American Society of Echocardiography guidelines and European Association of Cardiovascular Imaging consensus recommendations as a key criterion for grading LV filling pressure. For primary physicians, understanding the progression of LA functional assessment techniques, along with their respective strengths and limitations, is essential for selecting the modality most appropriate for a patient’s cardiovascular profile.
- Open Access
- 14 August 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (5) , 3667-3677
Decoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging
Aims: Baseline Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) scores and serial left ventricular global longitudinal strain (LV-GLS) measurements have been found to be useful in predicting cancer therapy-related cardiac dysfunction (CTRCD). However, their integration for the purpose of improving prognostic accuracy remains unclear; and we aimed to develop a predictive model for CTRCD using baseline HFA-ICOS scores and the relative decline of LV-GLS in patients on anthracycline or trastuzumab. Methods: We prospectively enrolled 443 chemotherapy-naïve women with breast cancer and cardiovascular risk factors, scheduled to receive anthracycline (n = 333) or trastuzumab (n = 110). Participants were stratified by the HFA-ICOS risk score. The left ventricular ejection fraction (LVEF) and LV-GLS were evaluated using echocardiography at baseline, before each treatment cycle, and every 3 months in the first year post-chemotherapy. CTRCD was a new LVEF reduction ≥10 percentage points to an LVEF < 50%, irrespective of symptoms. Results: In terms of HFA-ICOS stratification, 258 patients (58.2%) were low risk, 180 (40.6%) were moderate risk and 5 (1.2%) were high risk. The proportions of low- and moderate-risk patients were similar in the anthracycline and trastuzumab groups. Twenty-four (7.2%) and seven (6.4%) patients treated with anthracycline and trastuzumab, respectively, displayed asymptomatic CTRCD. The addition of the baseline HFA-ICOS risk score did not improve the performance of the significant relative decline of LV-GLS > 15% in predicting both anthracycline [area under the receiver-operating characteristic curve (AUC) 0.93, 95% confidence interval (CI) 0.89–0.96, sensitivity 87.5%, specificity 93.2%] and trastuzumab (AUC 0.97, 95% CI 0.88–0.99, sensitivity 85.7%, specificity 93.2%)-related cardiac dysfunction. Conclusions: Contemporary anthracycline and trastuzumab-based regimens resulted in similarly low incidences of CTRCD. In this context, LV-GLS evolution was the best predictor of CTRCD.
- 14 August 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (5) , 3667-3677
Open AccessDecoding Anthracycline- and Trastuzumab-Related Cardiac Dysfunction Prediction: HFA-ICOS Scores Versus Strain Imaging
Aims: Baseline Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) scores and serial left ventricular global longitudinal strain (LV-GLS) measurements have been found to be useful in predicting cancer therapy-related cardiac dysfunction (CTRCD). However, their integration for the purpose of improving prognostic accuracy remains unclear; and we aimed to develop a predictive model for CTRCD using baseline HFA-ICOS scores and the relative decline of LV-GLS in patients on anthracycline or trastuzumab. Methods: We prospectively enrolled 443 chemotherapy-naïve women with breast cancer and cardiovascular risk factors, scheduled to receive anthracycline (n = 333) or trastuzumab (n = 110). Participants were stratified by the HFA-ICOS risk score. The left ventricular ejection fraction (LVEF) and LV-GLS were evaluated using echocardiography at baseline, before each treatment cycle, and every 3 months in the first year post-chemotherapy. CTRCD was a new LVEF reduction ≥10 percentage points to an LVEF < 50%, irrespective of symptoms. Results: In terms of HFA-ICOS stratification, 258 patients (58.2%) were low risk, 180 (40.6%) were moderate risk and 5 (1.2%) were high risk. The proportions of low- and moderate-risk patients were similar in the anthracycline and trastuzumab groups. Twenty-four (7.2%) and seven (6.4%) patients treated with anthracycline and trastuzumab, respectively, displayed asymptomatic CTRCD. The addition of the baseline HFA-ICOS risk score did not improve the performance of the significant relative decline of LV-GLS > 15% in predicting both anthracycline [area under the receiver-operating characteristic curve (AUC) 0.93, 95% confidence interval (CI) 0.89–0.96, sensitivity 87.5%, specificity 93.2%] and trastuzumab (AUC 0.97, 95% CI 0.88–0.99, sensitivity 85.7%, specificity 93.2%)-related cardiac dysfunction. Conclusions: Contemporary anthracycline and trastuzumab-based regimens resulted in similarly low incidences of CTRCD. In this context, LV-GLS evolution was the best predictor of CTRCD.
- Open Access
- 27 November 2023
- Published by BMJ in Open Heart
- Vol. 10 (2) , e002493
Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection
Objective This study aimed to assess the incidence of early cancer therapy-related cardiac dysfunction (CTRCD) and the characteristics of left and right heart deformations during anthracycline chemotherapy. Methods We prospectively enrolled a cohort of 351 chemotherapy-naïve women with breast cancer and cardiovascular risk factors who were scheduled to receive anthracycline. The left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV-GLS) and right ventricular and left atrial longitudinal strains were evaluated using echocardiography at baseline, before every subsequent cycles and at 3 weeks after the final anthracycline dose. CTRCD was defined as a new LVEF reduction by ≥10 percentage points to an LVEF15% from the baseline value. Results Eighteen (5.1%) patients had evidence of asymptomatic CTRCD during anthracycline treatment, and 50% developed CTRCD before completing the chemotherapy regimen. In the CTRCD group, while LV-GLS decrease significantly after the first dose of anthracycline, the reduction of right ventricular free-wall longitudinal strain and left atrial reservoir strain were observed after the second dose. Other strain indices could not be used to identify early CTRCD. Conclusions Cardiotoxicity appeared soon after the initiation of anthracycline chemotherapy. Among the left-heart and right-heart mechanics, LV-GLS remains the best deformation indicator for detecting early CTRCD.
- 27 November 2023
- Published by BMJ in Open Heart
- Vol. 10 (2) , e002493
Open AccessSuperiority of left heart deformation in early anthracycline-related cardiac dysfunction detection
Objective This study aimed to assess the incidence of early cancer therapy-related cardiac dysfunction (CTRCD) and the characteristics of left and right heart deformations during anthracycline chemotherapy. Methods We prospectively enrolled a cohort of 351 chemotherapy-naïve women with breast cancer and cardiovascular risk factors who were scheduled to receive anthracycline. The left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV-GLS) and right ventricular and left atrial longitudinal strains were evaluated using echocardiography at baseline, before every subsequent cycles and at 3 weeks after the final anthracycline dose. CTRCD was defined as a new LVEF reduction by ≥10 percentage points to an LVEF15% from the baseline value. Results Eighteen (5.1%) patients had evidence of asymptomatic CTRCD during anthracycline treatment, and 50% developed CTRCD before completing the chemotherapy regimen. In the CTRCD group, while LV-GLS decrease significantly after the first dose of anthracycline, the reduction of right ventricular free-wall longitudinal strain and left atrial reservoir strain were observed after the second dose. Other strain indices could not be used to identify early CTRCD. Conclusions Cardiotoxicity appeared soon after the initiation of anthracycline chemotherapy. Among the left-heart and right-heart mechanics, LV-GLS remains the best deformation indicator for detecting early CTRCD.
- Open Access
- 27 January 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 783181
Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale
Background: Diuretic Resistance in Acute Heart Failure (DR-AHF) was designed to demonstrate the effectiveness of the early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in patients with AHF with renal dysfunction and to provide clinical evidence of loop diuretic resistance.Methods and Results: This single-centered, open-labeled, randomized, and controlled trial enrolled 128 patients hospitalized with AHF, as participants. These patients with a wet-warm phenotype, whose estimated glomerular filtration rates are of ≥15 ml/min/1.73 m2 and ≤ 60 ml/min/1.73 m2, with a cumulative urine output of <300 ml 2 h after the first dose of intravenous furosemide, will be randomly assigned 1:1 to receive standard care with an uptitrating intravenous furosemide alone, or a combination therapy with 15 mg of tolvaptan administered once daily for 2 days. The standard furosemide treatment will follow the latest position statements of the Heart Failure Association. The primary endpoint is the cumulative urine output at 48 h. The key secondary endpoints include the improvement of fractional excretion of sodium at 6 h, the total dose of furosemide, and the incidence of worsening renal function (WRF) at 48 h.Conclusions: Although the combination of diuretic treatment has recently gained more attention due to its physiologically synergistic action, its advantages may be outweighed by the substantial risk of electrolyte disturbances and severe WRF. Further, there is no consensus on the time point for early starting of add-on therapy and for the preferred diuretic combination.Trial registration: NCT04331132.
- 27 January 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 783181
Open AccessTolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale
Background: Diuretic Resistance in Acute Heart Failure (DR-AHF) was designed to demonstrate the effectiveness of the early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in patients with AHF with renal dysfunction and to provide clinical evidence of loop diuretic resistance.Methods and Results: This single-centered, open-labeled, randomized, and controlled trial enrolled 128 patients hospitalized with AHF, as participants. These patients with a wet-warm phenotype, whose estimated glomerular filtration rates are of ≥15 ml/min/1.73 m2 and ≤ 60 ml/min/1.73 m2, with a cumulative urine output of <300 ml 2 h after the first dose of intravenous furosemide, will be randomly assigned 1:1 to receive standard care with an uptitrating intravenous furosemide alone, or a combination therapy with 15 mg of tolvaptan administered once daily for 2 days. The standard furosemide treatment will follow the latest position statements of the Heart Failure Association. The primary endpoint is the cumulative urine output at 48 h. The key secondary endpoints include the improvement of fractional excretion of sodium at 6 h, the total dose of furosemide, and the incidence of worsening renal function (WRF) at 48 h.Conclusions: Although the combination of diuretic treatment has recently gained more attention due to its physiologically synergistic action, its advantages may be outweighed by the substantial risk of electrolyte disturbances and severe WRF. Further, there is no consensus on the time point for early starting of add-on therapy and for the preferred diuretic combination.Trial registration: NCT04331132.
- Open Access
- 25 June 2020
- Published by BMJ in Open Heart
- Vol. 7 (1) , e001173
Renal kinetics in acute heart failure
Aims Worsening renal function (WRF) in acute heart failure (AHF) has multifactorial pathophysiological mechanisms and heterogeneous prognostic impacts. The aim of this study was to determine the characteristics and renal kinetics of this phenomenon. Methods and results We prospectively enrolled a cohort of 196 patients admitted for AHF to the Cardiology Department at Nhan Dan Gia Dinh Hospital, from July 2016 to March 2017. AHF was defined using the 2012 European Society of Cardiology criteria. The definition and severity of WRF were based on the 2012 Kidney Disease Improving Outcome criteria for acute kidney injury. Renal recovery was classified using the 2017 Acute Disease Quality Initiative 16 Workgroup Consensus. Among the 196 patients studied, WRF developed in 43.4%. In 80.0% of patients, WRF occurred within 48 hours of admission. In the WRF group, 89.4% were at stage 1, consistent with a relative increase in median serum creatinine of 49.5%. A total of 76.5% of the patients with WRF recovered at discharge, while rapid recovery occurred in 20.0% of patients. Conclusions Most cases of WRF were mild, and WRF was correlated with a high rate of recovery during hospitalisation. However, rapid renal recovery was not common.
- 25 June 2020
- Published by BMJ in Open Heart
- Vol. 7 (1) , e001173
Open AccessRenal kinetics in acute heart failure
Aims Worsening renal function (WRF) in acute heart failure (AHF) has multifactorial pathophysiological mechanisms and heterogeneous prognostic impacts. The aim of this study was to determine the characteristics and renal kinetics of this phenomenon. Methods and results We prospectively enrolled a cohort of 196 patients admitted for AHF to the Cardiology Department at Nhan Dan Gia Dinh Hospital, from July 2016 to March 2017. AHF was defined using the 2012 European Society of Cardiology criteria. The definition and severity of WRF were based on the 2012 Kidney Disease Improving Outcome criteria for acute kidney injury. Renal recovery was classified using the 2017 Acute Disease Quality Initiative 16 Workgroup Consensus. Among the 196 patients studied, WRF developed in 43.4%. In 80.0% of patients, WRF occurred within 48 hours of admission. In the WRF group, 89.4% were at stage 1, consistent with a relative increase in median serum creatinine of 49.5%. A total of 76.5% of the patients with WRF recovered at discharge, while rapid recovery occurred in 20.0% of patients. Conclusions Most cases of WRF were mild, and WRF was correlated with a high rate of recovery during hospitalisation. However, rapid renal recovery was not common.